MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Vlad Vitoc Acquires 73,000 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc purchased 73,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of $1.37 per share, with a total value of $100,010.00. Following the acquisition, the chief executive officer directly owned 1,049,121 shares in the company, valued at $1,437,295.77. This trade represents a 7.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

MAIA Biotechnology Stock Up 6.9%

MAIA opened at $1.39 on Tuesday. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19. The company has a fifty day simple moving average of $1.35 and a 200 day simple moving average of $1.39. The stock has a market cap of $84.55 million, a P/E ratio of -2.24 and a beta of 0.25.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts expect that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors have recently modified their holdings of the business. Centric Wealth Management acquired a new position in shares of MAIA Biotechnology in the 2nd quarter valued at approximately $1,107,000. Cable Car Capital LP acquired a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $741,000. BlackRock Inc. acquired a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $580,000. Susquehanna International Group LLP bought a new position in MAIA Biotechnology in the second quarter valued at approximately $51,000. Finally, PVG Asset Management Corp bought a new position in MAIA Biotechnology in the first quarter valued at approximately $46,000. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.